Explore 3 Stock Ideas & Industry Insights Download Free Report

Genelux Corporation Common Stock

Company price
1.865 USD -0.04 ( 1.84%)
Last update at 2026-11-13T21:00:00Z
VOLUME
179403
Market Cap
111.76M

Momentum Score

…

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.83
Low
1.96
High
52 Week Price Range
2.29
Low
8.54
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Genelux Corporation appears positioned as a clinical-stage biotechnology company focused on oncolytic viral immunotherapies targeting solid tumors. Its long-term growth drivers include clinical data readouts, potential regulatory approvals and strategic partnerships that could support commercialization, and investors may find the company attractive because successful clinical outcomes could validate the platform and create significant oncology assets.
Major investment risks include clinical trial failure, regulatory setbacks, limited revenue and cash runway, dilution from future financing and strong competition in oncology; investors should monitor execution and funding needs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.90
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
0.01M
Debt / Equity
0.15
ROE
-177.93%
Net Debt
-3.65M
ROCE
-259.44%
Diluted EPS TTM
-0.86

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -32.15M -29.87M -28.30M -4.11M -16.38M
Net income -32.15M -29.87M -28.30M -5.21M -17.80M
Selling general administrative 13.37M 12.71M 11.57M 5.00M 8.29M
Selling and marketing expenses - - 1.02M - -
Gross profit -0.57M -0.90M -0.85M 11.07M -
Reconciled depreciation 0.57M 0.90M 1.06M 0.97M 0.90M
Ebit -33.21M -29.87M -27.48M -3.01M -14.61M
Ebitda -32.64M -28.97M -26.46M -2.04M -14.12M
Depreciation and amortization 0.57M 0.90M 1.02M 0.97M 0.50M
Operating income -33.21M -31.70M -24.16M -3.01M -14.61M
Other operating expenses 33.22M 31.70M 24.34M 14.08M 14.61M
Interest expense - 0.00M 3.97M 1.41M 1.42M
Tax provision - - 0.00M 1.10M -
Interest income 1.07M 1.46M 0.24M - -
Net interest income 1.07M 1.46M -4.37M -1.41M -1.81M
Income tax expense - - 0.85M 1.10M 1.42M
Total revenue 0.01M 0.01M 0.17M 11.07M 0.00M
Total operating expenses 32.65M 30.80M 23.32M 14.08M 14.61M
Cost of revenue 0.57M 0.90M 1.02M - -
Total other income expense net 1.07M 1.83M -4.13M -1.09M -1.76M
Net income from continuing ops -32.15M -29.87M -25.02M -5.21M -16.38M
Net income applicable to common shares - - - -5.21M -16.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19.03M 34.72M 27.89M 5.53M 8.13M
Other current assets 0.54M 0.65M 1.01M 1.50M 1.33M
Total liab 7.48M 8.44M 8.42M 41.31M 41.24M
Total stockholder equity 11.54M 26.27M 19.47M -35.78M -33.11M
Deferred long term liab - - - 1.57M -
Other current liab 5.80M 1.00M 2.12M 8.02M 6.96M
Common stock 0.04M 0.04M 0.03M 0.01M 0.01M
Capital stock 0.04M 0.04M 0.03M 0.03M 0.03M
Retained earnings -283.54M -251.39M -221.52M -189.78M -184.58M
Other assets - - - - 0.09M
Cash 5.33M 8.56M 9.42M 0.40M 4.50M
Total current liabilities 6.22M 6.90M 6.55M 31.63M 22.48M
Current deferred revenue - - - 0.17M 4.50M
Net debt -3.65M -6.70M -6.90M 25.96M 20.82M
Short term debt 0.43M 0.33M 0.65M 16.66M 6.56M
Short long term debt - - - 16.40M 6.16M
Short long term debt total 1.69M 1.87M 2.52M 26.35M 25.31M
Other stockholder equity 295.04M 277.57M 240.96M 153.97M 151.43M
Property plant equipment - - - - 2.21M
Total current assets 15.13M 31.55M 24.20M 1.89M 5.82M
Net tangible assets - - - - -33.13M
Short term investments 9.26M 22.33M 13.77M - -
Long term debt - - - 8.52M 18.02M
Accounts payable 4.36M 5.57M 3.78M 6.78M 4.46M
Accumulated other comprehensive income 0.01M 0.06M 0.01M 0.00M 0.00M
Non currrent assets other 0.14M 0.09M 0.09M 1.66M 0.09M
Non current assets total 3.90M 3.17M 3.69M 3.64M 2.30M
Capital lease obligations 1.69M 1.87M 2.52M 1.43M 1.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 13.24M -8.13M -0.78M -0.05M 0.00M
Change to liabilities - - - -4.33M 5.25M
Total cashflows from investing activities 12.14M -8.13M -14.72M -0.05M -0.05M
Net borrowings - 0.00M 0.21M - -0.56M
Total cash from financing activities 9.89M 28.51M 44.02M -0.48M -0.27M
Change to operating activities - - - - -1.17M
Net income -32.15M -29.87M -28.30M -5.21M -16.38M
Change in cash -3.23M -0.85M 9.02M -4.10M -6.86M
Begin period cash flow 8.56M 9.42M 0.40M 4.50M 11.35M
End period cash flow 5.33M 8.56M 9.42M 0.40M 4.50M
Total cash from operating activities -25.27M -21.23M -20.27M -3.57M -6.58M
Issuance of capital stock 9.66M 27.82M 39.65M 0.00M 0.14M
Depreciation 0.24M 0.90M 1.02M 0.97M 0.90M
Other cashflows from financing activities 9.89M 0.69M 4.16M -0.47M 1.08M
Change to netincome - - - 2.10M 4.62M
Capital expenditures 1.10M 0.38M 1.02M 0.05M 0.05M
Change in working capital -1.05M 0.75M -3.28M -1.69M 4.08M
Stock based compensation 5.87M 6.07M 5.20M 2.42M 4.27M
Other non cash items 1.81M 0.92M 5.08M -0.06M 0.20M
Free cash flow -26.37M -21.61M -21.30M -3.62M -6.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GNLX
Genelux Corporation Common Stock
-0.04
1.84%
1.86 - - 13969.50 7.15 12362.42 -327.19
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Genelux Corporation Common Stock

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

2625 Townsgate Road, Westlake Village, CA, United States, 91361

805 267 9889

25

Name Title Year Born
Mr. Thomas Zindrick J.D. Chairman, CEO & President 1960
Ms. Lourie S. Zak Chief Financial Officer 1964
Ms. Caroline Jewett VP & Head of Quality 1965
Dr. Joseph Cappello Ph.D. Chief Technical Officer 1957
Mr. Sean Ryder J.D. General Counsel & Corporate Secretary 1970
Dr. Yong Yu Ph.D. Senior Vice President of Clinical Development 1972
Prof. Paul Scigalla M.D., Ph.D. Chief Medical Officer 1946
Mr. Ralph Smalling B.Sc. VP & Head of Regulatory Affairs 1957
Mr. Thomas D. Zindrick J.D. Chairman, CEO & President 1960
Mr. Matthew Pulisic M.B.A. CFO and Principal Financial & Accounting Officer 1984

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…